The Presence of Anti-ribonucleoprotein at Diagnosis Is Associated with the Flare during the First Follow-up Year in Korean Patients with Systemic Lupus Erythematosus by 김대식 et al.
154
Received：October 27, 2015, Revised：December 6, 2015, Accepted：December 21, 2015 
Corresponding to：Sang-Won Lee, Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, 50-1 
Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea. E-mail：laza00@yuhs.ac
pISSN: 2093-940X, eISSN: 2233-4718
Copyright ⓒ 2016 by The Korean College of Rheumatology. All rights reserved.
This is a Free Access article, which permits unrestricted non-commerical use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original ArticleJournal of Rheumatic Diseases Vol. 23, No. 3, June, 2016http://dx.doi.org/10.4078/jrd.2016.23.3.154
The Presence of Anti-ribonucleoprotein at Diagnosis Is 
Associated with the Flare during the First Follow-up Year in 
Korean Patients with Systemic Lupus Erythematosus
Dae Sik Kim, Jung Yoon Pyo, Se-Jin Byun, Sung Soo Ahn, Jungsik Song, Yong-Beom Park, Soo-Kon Lee, 
Sang-Won Lee
Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
Objective. The aim of this study was to examine whether the presence of anti-ribonucleoprotein (anti-RNP) antibodies at diag-
nosis is associated with systemic lupus erythematosus (SLE) flares in newly diagnosed patients during the first year of follow-up. 
Methods. The medical records of 71 newly diagnosed SLE patients without other concomitant autoimmune disease, serious in-
fection, or malignancy were reviewed retrospectively. SLE flares were defined according to the SLE Disease Activity Index 
2000. Patients were divided into 2 groups according to the presence or absence of anti-RNP, and variables were compared be-
tween the groups. Results. During the first year of follow-up, SLE patients with anti-RNP at diagnosis more frequently presented 
with mucosal ulcers (p=0.003), rash (p=0.001), and arthritis (p=0.007), compared to those without anti-RNP. The SLE flare 
incidence was remarkably higher in patients with anti-RNP than in those without anti-RNP (62.5% vs. 23.1%, p=0.001). SLE 
patients with anti-RNP at diagnosis had a significantly higher risk of ever experiencing a SLE flare during the first year of fol-
low-up, compared to those without anti-RNP (odds ratio=8.250). Conclusion. In conclusion, SLE patients with anti-RNP at di-
agnosis were more than 8-fold more likely to experience an SLE flare during the first year of follow-up. (J Rheum Dis 2016;23:154- 
160)
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INTRODUCTION
Systemic lupus erythematosus (SLE) is a systemic auto-
immune disease characterized by various clinical manifes-
tations, depending on the affected organs and tissues. 
Dendritic cells and B cells are considered important play-
ers in the pathogenesis of SLE. In particular, the B cell pop-
ulations of patients with SLE may increase in both number 
and sensitivity to pro-inflammatory cytokine stimulation 
[1]. These cells can also produce diverse autoantibodies 
against self-antigens such as double-stranded (ds) DNA 
[1], and immune complexes containing these pathogenic 
autoantibodies may then deposit in organs and tissues and 
occasionally cause irreversible damage [2]. 
Anti-ribonucleoprotein (anti-RNP) autoantibodies, which 
recognize small nuclear RNA-protein complexes [3,4], are 
normally detected in a majority of patients with mixed 
connective tissue disease (MCTD), and anti-RNP titers 
have been reported to be correlate with the diseases and 
outcomes associated with MCTD [5,6]. In addition, an-
ti-RNP has been detected in a considerable proportion of 
SLE patients, although the role and clinical relevance of 
these autoantibodies in SLE activity remain controversial 
[7]. According to previous studies, the presence of an-
ti-RNP was thought to correlate with typical symptoms of 
MCTD, Raynaud’s phenomenon, and mild renal diseases 
in SLE patients [6,8]. In addition, SLE patients with an-
ti-RNP were found to more frequently manifest malar 
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rash, arthritis, and serositis [9], as well as a much higher 
prevalence of pulmonary hypertension or lung fibrosis 
higher SLE Disease Activity Index (SLEDAI) scores, com-
pared to SLE patients without anti-RNP [10,11]. 
However, to our knowledge, few studies have clarified the 
association between anti-RNP and changes in SLE activ-
ity, especially SLE flares, during a considerable follow-up 
period. Hence, in this study, we investigated whether the 
presence of anti-RNP at diagnosis was be associated with 
the incidence of SLE flares, defined according to the 
SLEDAI 2000 (SLEDAI-2K), in newly diagnosed SLE pa-
tients during the first year of follow-up [12,13].
MATERIALS AND METHODS
Patients
Using identification numbers, we retrospectively and 
consecutively reviewed the medical records of 105 pa-
tients who were initially diagnosed with SLE at Yonsei 
University Health System from January 2009 to 
December 2014. We finally enrolled 71 SLE patients who 
fulfilled the following inclusion criteria: (i) SLE diagnosis 
according to the 1997 American College of Rheumatology 
(ACR) classification criteria [12]; (ii) testing for comple-
ment components and anti-nuclear antibodies (ANA), 
anti-ds DNA, anti-Smith, anti-RNP, anti-Sjögren’s syn-
drome-related antigen A, anti-Sjögren’s syndrome-re-
lated antigen B, lupus anticoagulant, anti-cardiolipin, and 
anti-beta-2-glycoprotein-1 at diagnosis, in addition to 
tests for items listed in the SLEDAI-2K [13]; (iii) regular 
visits to our institute for at least 1 year after SLE diag-
nosis; and (iv) documented SLEDAI-2K scores at each 
visit during at least the first year of follow-up. We ex-
cluded SLE patients with other concomitant connective 
tissue diseases such as MCTD, serious infection, and/or 
malignancy, and those who were referred to our institute 
for previously diagnosed SLE. MCTD patients were ex-
cluded based on the criteria developed by 
Alargon-Segovia and by Kahn [14]. In this study, all pa-
tients were divided into 2 groups according to the pres-
ence of anti-RNP, and evaluated variables were compared 
between the groups. This study was approved by the 
Institutional Review Board of Severance Hospital, Seoul, 
South Korea.
Systemic lupus erythematosus disease activity
In the present study, we used SLEDAI-2K scores to as-
sess SLE disease activity; this was calculated using scores 
assigned to each SLEDAI-2K item present in the medical 
records of all patients [13]. We analyzed both the baseline 
SLEDAI-2K scores at diagnosis and the follow-up 
SLEDAI-2K scores either at the time of an SLE flare or 
during the last visit for SLE without flare during the first 
year of follow-up. An SLE flare was defined as a changes 
in the SLEDAI-2K score ＞4 points relative to the score 
from the previous visit. SLE without flare was defined as 
the absence of changes in SLEDAI-2K sufficient to meet 
the definition of SLE flare [15].
Clinical and laboratory data
All clinical manifestations were examined and docu-
mented in medical records by independent physicians at 
each visit [13,15]. Several clinically pathologic conditions 
were defined as follows: intestinal lung disease as the 
presence of reticular and/or interstitial opacities with or 
without ground glass opacities and/or honeycombing on 
chest X-ray or computed tomography scan; pleurisy on 
chest imaging as the presence of pleural effusion and 
pleural thickening; and pulmonary arterial hypertension 
as a pulmonary artery systolic pressure ＞35 mmHg via 
echocardiography [16]. The descriptions and definitions 
on the SLEDAI-2K data collection form were used as a ref-
erence for each clinical or laboratory item [13]. As a ma-
jority of patients with anti-RNP and Raynaud’s phenom-
enon had been classified as MCTD during the follow-up 
period, we did not include Raynaud’s phenomenon in the 
tables. ANA analysis was performed using an immuno-
fluorescent method (MBL International, Woburn, MA, 
USA); other antibodies, including anti-RNP, were meas-
ured using an automated fluoroimmunoassay analyzer 
(Elia; Phadia, Uppsala, Sweden). Lupus anticoagulants 
were assessed using the IL Test TM LAC Screen/Confirm 
Kit (Instrumentation Laboratory Co., Bedford, MA, USA).
Statistical analysis 
All statistical analyses were conducted using IBM SPSS 
Statistics ver. 21.0 (IBM Co., Armonk, NY, USA). Data 
and results are expressed as numbers (percentages) or 
medians (interquartile ranges). The chi-square test and 
Fisher’s exact test were applied to determine significant 
differences in categorical data between the 2 groups. For 
SLE flare, the odds ratio (OR) associated with the pres-
ence of anti-RNP was analyzed using a contingency table 
and the chi-square test. p-values ＜0.05 were considered 
statistically significant.
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RESULTS
Baseline characteristics of SLE patients and com-
parison of variables between patients with and 
without anti-RNP
The baseline characteristics are described in Table 1. The 
median age of the total cohort of 71 patients (5 men, 66 
women) was 43.2 years. The most common clinical fea-
ture was rash (39.4%), followed by arthritis (33.8%) and 
fever (12.7%). Of the laboratory results, low complement 
levels were found in 31 of 71 patients (43.7%), whereas 
increased DNA binding (anti-ds DNA) and leukopenia 
were observed in 21 patients (29.6%) and 17 patients 
(23.9%), respectively. The overall median SLEDAI-2K 
score was 6.0 (4.0 to 9.0). 
Anti-RNP was detected in 35 of 71 patients (49.3%). 
When patients were divided into 2 groups according to 
the presence of anti-RNP, SLE patients with anti-RNP 
more frequently manifested rash (18 [51.4%] vs. 10 
[27.8%], p=0.041) and arthritis (16 [45.7%] vs. 8 
[22.2%], p=0.036) than did those without anti-RNP at 
SLE diagnosis. The two groups did not differ significantly 
in other clinical features and laboratory results relevant to 
SLEDAI-2K. However, SLE patients with anti-RNP had a 
higher median baseline SLEDAI-2K score than did those 
without anti-RNP (8.0 vs. 5.0, p=0.002). Anti-Smith an-
tibodies were only detected in 11 SLE patients with an-
ti-RNP (p＜0.001). 
Comparison of variables related to the follow-up 
SLEDAI-2K scores and SLE flare rate during the first 
year of follow-up, according to the presence of 
anti-RNP
During the first follow-up year, SLE patients with RNP 
at diagnosis more frequently presented with mucosal ul-
cers (15 [42.9%] vs. 4 [11.1%], p=0.003), rash (14 
[40.0%] vs. 2 [5.6%], p=0.001), and arthritis (12 
[34.3%] vs. 3 [8.3%], p=0.007) than did those without 
anti-RNP. However, the groups did not differ significantly 
with regard to diffuse interstitial lung disease or pulmo-
nary arterial hypertension (Table 2). SLE patients with 
anti-RNP had a higher median follow-up SLEDAI-2K 
score, compared to those without anti-RNP (9.0 vs. 4.0, 
p＜0.001). The median changes in SLEDAI-2K scores in 
patients with and without anti-RNP were 0.7 and −0.9, 
respectively, a non-significant difference. However, the 
SLE flare incidence was remarkably higher in patients 
with anti-RNP than in those without anti-RNP (62.5% 
vs. 23.1%, p=0.001). Furthermore, patients with anti- 
RNP at the time of SLE diagnosis had a significantly high-
er risk of experienced any SLE flare during the first year of 
follow-up, compared to those without anti-RNP (OR= 
8.250, 95% confidence interval [CI] 2.121 to 32.090).
The 71 patients were further divided into 2 groups ac-
cording to the presence or absence of anti-Smith anti-
bodies at diagnosis (11 patients with anti-Smith vs. 60 
without), and the groups were compared with respect to 
the SLE flare rate. Notably, this rate (change in 
SLEDAI-2K score ≥4) was significantly higher in pa-
tients with anti-Smith antibodies than in those without 
anti-Smith antibodies (54.6% vs. 20.0%, p=0.025). 
Furthermore, patients with anti-Smith antibodies at the 
time of SLE diagnosis had a significantly higher risk of ex-
periencing SLE flare during the first year of follow-up 
(OR=4.800, 95% CI 1.251 to 18.421).
Anti-RNP titers were measured in 64 patients (31 pa-
tients with RNP, 33 patients without RNP). Consequently, 
a positive correlation was observed between the RNP 
titer and the SLE flare incidence (correlation coefficient= 
0.422, p=0.001). Finally, 57 of 71 patients (80.3%) re-
ceived systemic steroid treatment, and additional im-
munosuppressants (azathioprine, mycophenolate mofe-
til, cyclophosphamide) were administered to some pa-
tients (azathioprine 19.7%, mycophenolate mofetil 
11.3%, cyclophosphamide 5.6%). However, no statisti-
cally significant differences were observed between the 
two groups (Table 2). 
DISCUSSION
In this study, we found that SLE patients with anti-RNP 
at the time of the initial SLE diagnosis exhibited larger in-
creases in SLEDAI-2K scores during the first year of fol-
low-up than did patients without anti-RNP. In addition, 
the presence of anti-RNP appeared to predict an approx-
imately 8-fold increase in the SLE flare incidence during 
the same follow-up period. Moreover, our results sug-
gested that the presence of anti-RNP at diagnosis is asso-
ciated a greater incidence of arthritis and rash and may 
significantly promote the development of arthritis, rash, 
and mucosal ulcers, thus contributing to SLE flare accord-
ing to the SLEDAI-2K definition, a finding that was con-
sistent with the results of a previous study [9]. On the 
other hand, in contrast to previously reported results, the 
incidence of diffuse interstitial lung disease and pulmo-
nary arterial hypertension did not differ according to the 
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Demographic data 　 　 　 　
  Age (yr) 43.2 (37.0∼55.0) 43.0 (37.0∼53.0) 46.0 (35.0∼57.0) 0.328
  Female gender 66 (93.0) 33 (94.3) 33 (91.7) 1.000
SLEDAI-2K
  Clinical features 
    Seizure 1 (1.4) 0 (0) 1 (2.8) 1.000
    Psychosis 0 (0) 0 (0) 0 (0) 1.000
    Organic brain syndrome 0 (0) 0 (0) 0 (0) 1.000
    Visual disturbance 0 (0) 0 (0) 0 (0) 1.000
    Lupus headache 0 (0) 0 (0) 0 (0) 1.000
    Cerebrovascular accident 0 (0) 0 (0) 0 (0) 1.000
    Vasculitis 0 (0) 0 (0) 0 (0) 1.000
    Arthritis 24 (33.8) 16 (45.7) 8 (22.2) 0.036
    Myositis 0 (0) 0 (0) 0 (0) 1.000
    Pleurisy 6 (8.5) 3 (8.6) 3 (8.3) 1.000
    Pericarditis 2 (2.8) 2 (5.7) 0 (0) 0.239
    Rash 28 (39.4) 18 (51.4) 10 (27.8) 0.041
    Alopecia 3 (4.2) 1 (2.9) 2 (5.6) 1.000
    Mucosal ulcers 6 (8.5) 5 (14.3) 1 (2.8) 0.107
    Fever 9 (12.7) 5 (14.3) 4 (11.1) 0.735
  Laboratory results 
    Urinary casts 1 (1.4) 1 (2.9) 0 (0) 0.493
    Hematuria 14 (19.7) 10 (28.6) 4 (11.1) 0.065
    Proteinuria 16 (22.5) 10 (28.6) 6 (16.7) 0.230
    Pyuria 13 (18.3) 8 (22.9) 5 (13.9) 0.329
    Low complements 31 (43.7) 14 (40.0) 17 (47.2) 0.540
    Increased DNA binding 21 (29.6) 9 (25.7) 12 (33.3) 0.482
    Thrombocytopenia 12 (16.9) 3 (8.6) 9 (25.0) 0.065
    Leukopenia 17 (23.9) 9 (25.7) 8 (22.2) 0.730
  Score 6.0 (4.0∼9.0) 8.0 (5.0∼11.0) 5.0 (3.0∼6.0) 0.002
Autoantibodies 
  Antinuclear antibody 66 (93.0) 34 (97.1) 32 (88.9) 0.357
  Anti-double strand DNA 21 (29.6) 9 (25.7) 12 (33.3) 0.482
  Anti-Smith 11 (15.5) 11 (31.4) 0 (0) ＜0.001
  Anti-SSA/Ro 35 (49.3) 20 (57.1) 15 (41.7) 0.192
  Anti-SSB/La 14 (19.7) 8 (22.9) 6 (16.7) 0.512
  Lupus anticoagulant 13 (18.3) 9 (25.7) 4 (11.1) 0.112
  Anti-cardiolipin 8 (11.3) 3 (8.6) 5 (13.9) 0.710
  Anti-beta2-glycoprotein1 8 (11.3) 5 (14.3) 3 (8.3) 0.478
Other clinical features
  Diffuse interstitial lung diseases 1 (1.4) 1 (2.9) 0 (0) 0.493
  Pulmonary arterial hypertension 0 (0) 0 (0) 0 (0) 1.000
Values are presented as median (interquartile range) or number (%). SLEDAI-2K: systemic lupus erythematosus Disease Activity 
Index 2000, RNP: ribonucleoprotein, SSA/Ro: Sjögren's syndrome-related antigen A, SSB/La: Sjögren's syndrome-related antigen
B.
presence of anti-RNP [10]. However, a 1-year follow-up 
period might not be sufficient to identify histological al-
terations that lead to clinical symptoms.
In general clinical situations, physicians tend to monitor 
follow-up anti-ds DNA titer and complement component 
levels to assess SLE disease activity; however, no current 
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Table 2. Comparison of variables of the follow-up SLEDAI-2K scores and SLE flare rate during the first follow-up year between SLE







Demographic data 　 　 　
  Follow-up period (mo) 11.0 (8.0∼11.0) 11.0 (11.0∼12.0) 0.077
SLEDAI-2K at flare
  Clinical features 
    Seizure 0 (0) 0 (0) NA
    Psychosis 0 (0) 1 (2.8) 1.000
    Organic brain syndrome 0 (0) 0 (0) NA
    Visual disturbance 0 (0) 0 (0) NA
    Lupus headache 2 (5.7) 0 (0) 0.239
    Cerebrovascular accident 0 (0) 0 (0) NA
    Vasculitis 0 (0) 0 (0) NA
    Arthritis 12 (34.3) 3 (8.3) 0.007
    Myositis 0 (0) 0 (0) NA
    Pleurisy 4 (11.4) 3 (8.3) 0.710
    Pericarditis 1 (2.9) 1 (2.8) 1.000
    Rash 14 (40.0) 2 (5.6) 0.001
    Alopecia 4 (11.4) 2 (5.6) 0.429
    Mucosal ulcers 15 (42.9) 4 (11.1) 0.003
    Fever 6 (17.1) 2 (5.6) 0.151
  Laboratory results 
    Urinary casts 5 (14.3) 0 (0) 0.025
    Hematuria 4 (11.4) 5 (13.9) 0.036
    Proteinuria 10 (28.6) 6 (16.7) 0.230
    Pyuria 11 (31.4) 4 (11.1) 0.329
    Low complement 13 (37.1) 11 (30.6) 0.557
    Increased DNA binding 8 (22.9) 10 (27.8) 0.634
    Thrombocytopenia 9 (25.7) 9 (25.0) 0.945
    Leukopenia 11 (31.4) 11 (30.6) 0.937
  Score 9.0 (7.0∼10.0) 4.0 (2.0∼6.8) ＜0.001
    Change in score 0.7 −0.9 0.142
    Flare of SLE 15 (62.5) 3 (23.1) 0.001
Other clinical features 
  Diffuse interstitial lung diseases 4 (11.4) 0 (0) 0.054
  Pulmonary arterial hypertension 3 (8.6) 1 (2.8) 0.357
Treatment 
  Hydroxychloroquine 31 (88.6) 30 (83.3) 0.735
  Steroid 27 (77.1) 30 (83.3) 0.563
  Azathioprine 7 (20.0) 7 (19.4) 1.000
  Mycophenolate mofetil 5 (14.3) 3 (8.3) 0.478
  Cyclophosphamide 3 (8.6) 1 (2.8) 0.357
Values are presented as median (interquartile range) or number (%). NA: not available, RNP: ribonucleoprotein, SLE: systemic 
lupus erythematosus, SLEDAI-2K: SLE Disease Activity Index 2000.
recommendations encourage the evaluation of other au-
toantibodies, including anti-RNP. In contrast to anti-ds 
DNA, anti-RNP can be detected in the peripheral blood 
for more than 1 year. In addition, because anti-RNP is 
produced by long-lived plasma cells and supported by the 
enhanced differentiation of anti-RNP-related memory B 
cells to plasma cells, the circulating anti-RNP concen-
tration might also be maintained despite the lack of an ex-
act established blood-survival time [14,17]. The long sta-
bility of anti-RNP renders it unsuitable as a marker of rap-
id alterations in SLE disease activity. Nevertheless, an-
ti-RNP may be useful for anticipating SLE flare, improve-
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ment, or remission during a lengthy follow-up period 
once its clinical relevance has been determined. Accor-
dingly, our present study of the potentially predictive and 
reflective role of anti-RNP positivity at the time of SLE di-
agnosis with regard to alterations in SLE disease activity 
within the first year of follow-up year after diagnosis was 
conducted against the backdrop of these concepts and 
characteristics of anti-RNP. 
Because the anti-ds DNA titer and complement compo-
nent levels are SLEDAI-2K items and are known to be re-
flective of changes in activity within a relatively short 
time period, we did not analyze their predictive potential 
for SLE flare in this study. In contrast, we assumed that 
the presence of anti-Smith antibodies might be predictive 
of SLE flare in the early phase of disease, as all 11 patients 
with anti-Smith antibodies were also anti-RNP-positive. 
Anti-Smith antibodies and anti-RNP might be simulta-
neously detected at a high rate in SLE patients, as these 
autoantibodies were classified and analyzed in the same 
cluster in previous studies [9,17]. In the present study; 
however, anti-Smith antibodies were only detected in pa-
tients having anti-RNP, and therefore we could not dis-
tinguish the direct effect of anti-Smith antibodies from 
the mutual effect of both types of autoantibodies. 
Therefore, the predictive potential of anti-Smith anti-
bodies with regard to SLE flare should be addressed in fu-
ture studies involving a greater number of anti-Smith an-
tibody-positive SLE patients. 
One feature of our study that we consider to be a strength 
is that it is the first to propose the potential of anti-RNP at 
diagnosis to predict the development of SLE flare during 
the first year of follow-up using the well- documented 
SLEDAI-2K at each visit. However, our study also had sev-
eral limitations. First, the study featured a small number 
of SLE patients and a relatively short follow-up period be-
cause of the exclusion criteria for concomitant MCTD and 
the retrospective design. Second, we were unable to ex-
plain the mechanism linking anti-RNP and the clinical 
items of SLEDAI-2K that contribute to SLE flare. Third, 
given the small number of patients, differences in baseline 
SLEDAI-2K scores between the two groups might have af-
fected the SLE flare rate, despite speculation regarding the 
relationship between the presence of anti-RNP and base-
line SLEDAI-2K scores. Future studies will be needed to 
compensate for these limitations and clarify the clinical 
role of anti-RNP for the prediction of the disease activity in 
newly diagnosed SLE patients. 
CONCLUSION
In conclusion, our study determined that among Korean 
SLE patients, those with anti-RNP at the time of diag-
nosis were 8.3-fold more likely to experience an SLE flare 
according to the SLEDAI-2K definition during the first 
year of follow-up relative to those without anti-RNP, thus 
indicating the potential predictive value of this auto-
antibody. 
CONFLICT OF INTEREST
No potential conflict of interest relevant to this article 
was reported.
REFERENCES
1. Mok CC, Lau CS. Pathogenesis of systemic lupus erythema-
tosus. J Clin Pathol 2003;56:481-90.
2. Rahman A, Isenberg DA. Systemic lupus erythematosus. N 
Engl J Med 2008;358:929-39.
3. Benito-Garcia E, Schur PH, Lahita R; American College of 
Rheumatology Ad Hoc committee on immunologic testing 
guidelines. Guidelines for immunologic laboratory testing 
in the rheumatic diseases: anti-Sm and anti-RNP antibody 
tests. Arthritis Rheum 2004;51:1030-44.
4. Greidinger EL, Hoffman RW. The appearance of U1 RNP 
antibody specificities in sequential autoimmune human an-
tisera follows a characteristic order that implicates the 
U1-70 kd and B'/B proteins as predominant U1 RNP 
immunogens. Arthritis Rheum 2001;44:368-75.
5. Cappelli S, Bellando Randone S, Martinović D, Tamas MM, 
Pasalić K, Allanore Y, et al. "To be or not to be," ten years af-
ter: evidence for mixed connective tissue disease as a dis-
tinct entity. Semin Arthritis Rheum 2012;41:589-98.
6. Lundberg I, Hedfors E. Clinical course of patients with an-
ti-RNP antibodies. A prospective study of 32 patients. J 
Rheumatol 1991;18:1511-9.
7. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, 
Dennis GJ, James JA, et al. Development of autoantibodies 
before the clinical onset of systemic lupus erythematosus. N 
Engl J Med 2003;349:1526-33.
8. Cozzani E, Drosera M, Gasparini G, Parodi A. Serology of lu-
pus erythematosus: correlation between immunopatho-
logical features and clinical aspects. Autoimmune Dis 
2014;2014:321359.
9. Li PH, Wong WH, Lee TL, Lau CS, Chan TM, Leung AM, et 
al. Relationship between autoantibody clustering and clin-
ical subsets in SLE: cluster and association analyses in Hong 
Kong Chinese. Rheumatology (Oxford) 2013;52:337-45.
10. Allen D, Fischer A, Bshouty Z, Robinson DB, Peschken CA, 
Hitchon C, et al. Evaluating systemic lupus erythematosus 
patients for lung involvement. Lupus 2012;21:1316-25.
11. Carpintero MF, Martinez L, Fernandez I, Romero AC, Mejia 
C, Zang YJ, et al. Diagnosis and risk stratification in patients 
with anti-RNP autoimmunity. Lupus 2015;24:1057-66.
Dae Sik Kim et al.
160 J Rheum Dis Vol. 23, No. 3, June, 2016
12. Hochberg MC. Updating the American College of 
Rheumatology revised criteria for the classification of sys-
temic lupus erythematosus. Arthritis Rheum 1997;40:1725.
13. Gladman DD, Ibañez D, Urowitz MB. Systemic lupus eryth-
ematosus disease activity index 2000. J Rheumatol 
2002;29:288-91.
14. Amigues JM, Cantagrel A, Abbal M, Mazieres B. 
Comparative study of 4 diagnosis criteria sets for mixed 
connective tissue disease in patients with anti-RNP 
antibodies. Autoimmunity Group of the Hospitals of 
Toulouse. J Rheumatol 1996;23:2055-62.
15. Touma Z, Urowitz MB, Ibañez D, Gladman DD. SLEDAI-2K 
10 days versus SLEDAI-2K 30 days in a longitudinal 
evaluation. Lupus 2011;20:67-70.
16. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, 
Olschewski H, et al. Diagnosis and differential assessment 
of pulmonary arterial hypertension. J Am Coll Cardiol 
2004;43(12 Suppl S):40S-7S.
17. Weinstein JS, Delano MJ, Xu Y, Kelly-Scumpia KM, 
Nacionales DC, Li Y, et al. Maintenance of anti-Sm/RNP au-
toantibody production by plasma cells residing in ectopic 
lymphoid tissue and bone marrow memory B cells. J 
Immunol 2013;190:3916-27.
